Evidence map›Paper›PMID 32457410›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Molecular patterns in salivary duct carcinoma identify prognostic subgroups.

Simon A Mueller, Marie-Emilie A Gauthier, James Blackburn, John P Grady, Spiridoula Kraitsek, Elektra Hajdu, Matthias S Dettmer, Jane E Dahlstrom, C Soon Lee, Peter P Luk and 6 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Simon A MuellerThe Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, NSW, Australia. simon.mueller@insel.ch.ORCID http://orcid.org/0000-0001-9318-7270
Marie-Emilie A GauthierThe Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
James BlackburnCancer Research Theme, Garvan Institute of Medical Research, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-5216-8815
John P GradyKinghorn Cancer Centre and Garvan Institute of Medical Research, Sydney, NSW, Australia.
Spiridoula KraitsekDepartment of Medical Genomics, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, NSW, Australia.
Elektra HajduKinghorn Cancer Centre and Garvan Institute of Medical Research, Sydney, NSW, Australia.
Matthias S DettmerInstitute of Pathology, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0003-0948-1392
Jane E DahlstromDepartment of Anatomical Pathology, ACT Pathology, Canberra Hospital and Australian National University Medical School, College of Health and Medicine, Woden, ACT, Australia.
C Soon LeeCentre for Oncology Education and Research Translation (CONCERT), Liverpool, NSW, Australia.
Peter P LukThe Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-8779-4461
Bing YuDepartment of Medical Genomics, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-6013-5220
Roland GigerDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Sarah KummerfeldKinghorn Cancer Centre and Garvan Institute of Medical Research, Sydney, NSW, Australia.
Jonathan R ClarkThe Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
Ruta Gupta *The Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
Mark J Cowley *Kinghorn Cancer Centre and Garvan Institute of Medical Research, Sydney, NSW, Australia.
Garvan Institute of Medical Research · AUThe University of Sydney · AUUniversity of Bern · CHRoyal Prince Alfred Hospital · AUAustralian National University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salivary duct carcinoma (SDCa) is a rare cancer with high rate of metastases and poor survival despite aggressive multimodality treatment. This study analyzes the genetic changes in SDCa, their impact on cancer pathways, and evaluates whether molecular patterns can identify subgroups with distinct clinical characteristics and outcome. Clinicopathologic details and tissue samples from 66 patients (48 males, 18 females) treated between 1995 and 2018 were obtained from multiple institutions. Androgen receptor (AR) was assessed by immunohistochemistry, and the Illumina TruSight 170 gene panel was used for DNA sequencing. Male gender, lympho-vascular invasion, lymph node metastasis, and smoking were significant predictors of disease-free survival. AR was present in 79%. Frequently encountered alterations were mutations in TP53 (51%), PIK3CA (32%) and HRAS (22%), as well as amplifications of CDK4/6 (22%), ERBB2 (21%), MYC (16%), and deletions of CDKN2A (13%). TP53 mutation and MYC amplifications were associated with decreased disease-free survival. Analysis of cancer pathways revealed that the PI3K pathway was most commonly affected. Alterations in the cell cycle pathway were associated with impaired disease-free survival (HR 2.6, P = 0.038). Three subgroups based on AR and ERBB2 status were identified, which featured distinct molecular patterns and outcome. Among AR positive SDCa, HRAS mutations were restricted to AR positive tumors without ERBB2 amplification and HRAS mutations featured high co-occurrence with PIK3CA alterations, which seems specific to SDCa. AR negative SDCa were associated with poor disease-free survival in multivariate analysis (HR 4.5, P = 0.010) and none of these tumors exhibited ERBB2 amplification or HRAS mutations. AR and ERBB2 status in SDCa thus classifies tumors with distinct molecular profiles relevant to future targeted therapy. Furthermore, clinical factors such as smoking and molecular features such as MYC amplification may serve as markers of poor prognosis of SDCa.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, DuctalFemaleHumansMaleMiddle AgedPrognosisSalivary Gland NeoplasmsBiomarkers, Tumor

Identifiers

PMID32457410
OpenAlexW3031298245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.